Pharmacovigilance in a paediatric intensive care unit;Farmacovigilancia en una unidad de cuidados intensivos pediátricos

Farmacia Hospitalaria

Volumn 30, Issue 4, 2006, Pages 249-253

  Rousseau, M N ^a   Travaglianti, M ^a   Vega, E M ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Drug related adverse events; Pediatric intensive care unit; Pharmacovigilance

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HUMAN; INFANT; INTENSIVE CARE; KIDNEY DISEASE; MALE; MULTIPLE ORGAN FAILURE; PEDIATRICS; PHARMACIST; SKIN MANIFESTATION; DRUG THERAPY; PRESCHOOL CHILD; SAFETY;

CHILD, PRESCHOOL; DRUG THERAPY; FEMALE; HUMANS; INFANT; INTENSIVE CARE UNITS, PEDIATRIC; MALE; SAFETY MANAGEMENT;

EID: 33750037615     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)73983-6     Document Type: Article

References (21)

1. Vargas E, Puerro M, Moreno A, Simón J, González-Callejo MA, Jaime M, et al. Effect of adverse drug reactions on length of stay in Intensive Care Units. Clin Drug Invest 1998; 15: 353-60.
2. Tiberio G, Hueto J, Moreno M, García de Lucas L, Sánchez Álvarez J, Nagore C, et al. Reacciones adversas medicamentosas: algoritmos de Naranjo y Venulet. Rev Clin Esp 1992; 191: 270-3.
3. Davies DM. Adverse drug reactions. J Prac Pharm 1987; 5: 127-32.
4. Porter J, Hick H. Drug-related deaths among medical inpatients. JAMA 1977; 237: 879-81.
5. Schneider PJ, Gift MG, Lee YP, Rothermich EA, Sill BE. Cost of medication-related problems at a university hospital. Am J Health-Sys Pharm 1995; 52: 2415-8.
6. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
7. Rosenberg DI, Moss MM. Guidelines and levels of care for Pediatric Intensive Care Units. Crit Care Med 2004; 32: 2117-27.
8. Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring. Vigilancia de la seguridad de los medicamentos. Guía para la instalación y puesta en funcionamiento de un centro de Farmacovigilancia. 2001, [consultado en julio 2005]. Disponible en: http://www.who-umc.org/pdfs/guidelinesspa.pdf
9. Calle G, Rousseau M, Hermilia M, Lemos L. Evaluación y prevención de reacciones adversas. Farmacovigilancia, experiencia en el Hospital Garrahan. Medicina Infantil. Revista del Hospital de Pediatría Garrahan 2004; 11: 94-100.
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
11. Winterstein AG, Hatton RC, Gonzalez Rothi R. Significant clinically preventable adverse drug events through a Hospital's database of adverse drug reaction reports. Am J Health-Syst Pharm 2002; 59: 1742-9.
12. Kanjanarat P, Winterstein GA, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in Hospitals: A literature review. Am J Health-Syst Pharm 2003; 60: 1750-9.
13. Gill AM, Leach HJ, Hugehs J, Barker C, Nunn AJ, Choonara I. Adverse drug reactions in paediatric intensive care unit. Acta Paediatr 1995; 84: 438-41.
14. Temple ME, Robinson RF, Miller JC, Hayes JR, Nahata MC. Frequency and preventability of adverse drug reactions in paediatric patients. Drug safety 2004; 27: 819-29.
15. Karson AS, Bates DW. Screening for adverse events. J Eval Clin Pract 1999; 5: 23-32.
16. Talbot EA, Perkins M, Silva S, Frothingham R. Disseminad bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 1997; 24: 1139-45.
17. Ioannidis M. Drug-induced renal failure in the ICU. Int J Artif Organs 2004; 27: 1034-42.
18. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001; 137: 357-64.
19. Wolkenstein P, Revuz J. Drug-induced severe skin reactions-incidence, management and prevention. Drug Safety 1995; 13: 56-68.
20. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the Intensive Care Unit. JAMA 1999; 282: 267-70.
21. Thompson CA. Preventable adverse events decline when pharmacist joins general medicine rounds. Am J Health-Syst Pharm 2003; 60: 2282-3.